NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinoma
Preprint
Abstract
SUMMARY: ∼30% of clear cell renal cell carcinoma (ccRCC) patients present with metastatic disease at the time of diagnosis, causing a dire 5-year survival rate of 13%. Whereas anti-PD-1 immunotherapy has improved survival, a strong need remains for new therapeutic options. Using integrated network analysis, we identified the mitotic regulator NDC80 as a predictor of ccRCC progression. Overexpression of NDC80 fosters the malignant phenotype by promoting cell cycle progression through S phase as well as boosting glycolysis and mitochondrial respiration. Despite high levels of immune infiltration, particularly derived from tumor resident CD8+ T cells with an exhausted phenotype, NDC80 defines a class of ccRCCs that poorly respond to immune checkpoint blockade. Instead, bioinformatics identified NDC80-high ccRCCs as sensitive to inhibitors of mitotic kinases, PLK1 and AURK, therapeutic approaches we validated in cell lines and mouse xenograft studies. Thus, NDC80 status pinpoints mitotic kinase inhibitors as promising therapeutic options in difficult-to-treat ccRCCs.Keywords
All Related Versions
- Published version: iScience, 26 (4), 106531.
This publication has 48 references indexed in Scilit:
- Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingNature Genetics, 2014
- Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1Journal of Experimental & Clinical Cancer Research, 2014
- Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applicationsNature Protocols, 2013
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growthJournal of Gastroenterology, 2013
- Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxelActa Pharmacologica Sinica, 2013
- Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivoProceedings of the National Academy of Sciences, 2008
- Hec1 and Nuf2 Are Core Components of the Kinetochore Outer Plate Essential for Organizing Microtubule Attachment SitesMolecular Biology of the Cell, 2005